相关实验视频

Updated: Sep 19, 2025

A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate NMDA Receptor in Blood

A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate NMDA Receptor in Blood

Published on: January 9, 2018

单克隆人性化单价抗体阻断疗法用于抗NMDA受体脑炎

Atsuo Kanno^1,2, Takuya Kito², Masashi Maeda^1,2

¹Arialys Therapeutics, Inc., La Jolla, CA, USA.

Nature communications

|June 17, 2025

概括

一种新疗法,ART5803,在治疗抗NMDA受体 (NMDAR) 脑炎方面表现有前途. 这种抗体阻断了致病性自身抗体效应,恢复了NMDAR功能,并迅速扭转了动物模型中的疾病症状.

科学领域:

神经免疫学神经免疫学
神经学神经学
药理学药理学是指药理学的学科.

背景情况:

抗NMDA受体 (NMDAR) 脑炎是一种严重的自身免疫神经系统疾病.
针对NMDAR GluN1亚单元的N-终端域 (NTD) 的致病性自身抗体通过交叉链接和内化NMDARs引起疾病.
目前的治疗方法对于这种破坏性疾病缺乏特异性和快速有效性.

研究的目的:

评估ART5803,一个人性化的单价抗体,作为抗NMDAR脑炎的潜在治疗剂.
研究ART5803在阻断致病性自身抗体效应和恢复NMDAR功能方面的作用机制.
在临床前模型中评估ART5803的疗效和药理动力学概况.

主要方法:

在体外评估了ART5803的结合亲和力和对NMDAR活性和内化的影响.
使用脑内静脉 (ICV) 自体抗体的使用,建立了抗NMDAR脑炎的马尔莫塞特模型.
在动物模型中,通过ICV输液和外周注射来评估ART5803的疗效.
在Cynomolgus子中进行了药理动力学研究.

主要成果:

在没有改变基底NMDAR功能的情况下,ART5803向GluN1-NTD显示了高亲和度结合 (K_D = 0.69nM).
ART5803有效地阻止了自身抗体诱导的NMDAR内部化,并恢复了NMDAR功能.
在海模型中,ART5803在ICV或外周给药后迅速扭转了行为和运动异常.
在Cynomolgus子中观察到有利的药理动力学特性.

结论:

ART5803是抗NMDAR脑炎的一个有前途的治疗候选药物.
该抗体通过防止致病性自身抗体介导的NMDAR内部化和恢复受体功能来起作用.
临床前数据支持静脉注射ART5803作为快速起作用和有效的治疗选择的潜力.

更多相关视频

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

Published on: November 23, 2013

Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis

Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis

Published on: June 2, 2022

相关概念视频

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.

Antiepileptic Drugs: Glutamate Antagonists

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...